LEXINGTON, Mass., Oct. 31, 2019 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, will release
its third quarter 2019 financial results before the market opens on
Monday, November 4, 2019. Agenus
executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results
and provide a business update.
To access the live call, dial 1-844-492-3727 (U.S.) or
1-412-317-5118 (International) and ask to be joined into the Agenus
call. The call will also be webcast and will be accessible from the
Company's website at
http://investor.agenusbio.com/presentation-webcasts or with this
link https://www.webcaster4.com/Webcast/Page/1556/31794. A replay
will be available on the Company's website approximately two hours
after the call.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing a number of combination approaches that leverage a broad
repertoire of antibody therapeutics and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please visit www.agenusbio.com; information that
may be important to investors will be routinely posted on our
website.
Contact
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original
content:http://www.prnewswire.com/news-releases/agenus-to-report-third-quarter-2019-financial-results-on-november-4-2019-and-host-conference-call-and-webcast-300949271.html
SOURCE Agenus Inc.